# ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants

> **NCT06293742** · PHASE1 · COMPLETED · sponsor: **Eccogene** · enrollment: 48 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** ECC5004
- **DRUG:** Midazolam
- **DRUG:** Rosuvastatin
- **DRUG:** Digoxin
- **DRUG:** Atorvastatin

## Key facts

- **NCT ID:** NCT06293742
- **Lead sponsor:** Eccogene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-08
- **Primary completion:** 2024-04-15
- **Final completion:** 2024-04-15
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2024-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06293742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06293742, "ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06293742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*